
Lori Ann Panther MD MPH
Vice President, Clinical Development, Infectious Diseases, Moderna, Inc.
Join to View Full Profile
200 Technology SquareCambridge, MA 02139
Dr. Panther is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of WashingtonFellowship, Infectious Disease, 1990 - 1993
- University of California (San Francisco)Residency, Internal Medicine, 1986 - 1990
- University of Iowa Roy J. and Lucille A. Carver College of MedicineClass of 1986
Certifications & Licensure
- MA State Medical License 1994 - 2022
Publications & Presentations
PubMed
- 11 citationsSafety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial.Carlos Fierro, Daniel Brune, Marian Shaw, Howard Schwartz, Conor Knightly
The Journal of Infectious Diseases. 2024-09-23 - 18 citationsHuman Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF5...Xintao Hu, Krithika P Karthigeyan, Savannah Herbek, Sarah M Valencia, Jennifer A Jenks
The Journal of Infectious Diseases. 2024-08-16 - 7 citationsCharacterization of humoral and cellular immunologic responses to an mRNA-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults.Kai Wu, Yixuan Jacob Hou, Dan Makrinos, Runxia Liu, Alex Zhu
Journal of Virology. 2024-04-16
Press Mentions
- Investigational Vaccine Targeting CMV, the #1 Infectious Cause of Birth Defects in the U.S.June 3rd, 2022
- Pursuing Victory: Moderna Begins Dosing in Phase III CMV TrialNovember 8th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: